



(Shutterstock)

# China exposure: Toughing out the tariffs

04 December 2024, 3:24 pm MYT, written by UBS Editorial Team

**With financial markets focusing on the impending risk of higher US tariff rates, China's equity markets have come under pressure. Investors might be tempted to overreact to this threat and the likely attendant increased volatility. We would caution against this and advise investors to maintain a Neutral portfolio weighting on China equities but skew it toward defensives. In the fixed income space, the high all-in yields offered by Asia IG are still attractive.**

In the wake of Donald Trump's presidential election win in the US, the 3-week climb for China equities began to reverse. While disappointment over Beijing's policy stimulus contributed to the negativity, growing market expectations of higher US tariff rates in the months to come are probably the greater and the more enduring driver. The new US administration's cabinet selections have also provided increasing clarity on its seriousness about using tariffs, likely contributing to the accelerated decline in both the CSI 300 and the MSCI China (MXCN) over the past week. With tariff-related uncertainty likely to continue, if not intensify, investors are likely to continue to feel stressed about their exposure to China.

Notwithstanding the continued uncertainty, investors should avoid getting tunnel vision—there are other important drivers for the performance of China's equity markets. Chief amongst these would be the policy stimulus that China's policymakers are likely to enact as a countermeasure to the US tariffs. An attendant determinant for China's policy response, and thus financial markets, will be the pace of tariff rate hikes, especially with respect to China. We would thus advise investors to avoid knee-jerk reactions to news headlines, and instead stay the course and make incremental adjustments to well-diversified and balanced portfolios.

Our base case is that we are likely to only see selective (targeted) tariffs, and these are most likely to be phased in only gradually. We suspect that universal tariffs will be a lot harder to pull off politically, and that the Trump administration is

more likely (at a 65% probability) to instead resort to tariffs on a range of goods or sectors from a country or region based on those powers afforded to the US president. In our base case, we expect the effective US tariff rate on all Chinese goods to be gradually raised to 30% from the current 10% by end-2026, with initial steps by mid-2025. And we see China's GDP growth suffering a cumulative hit of 70-100 bps over three years. We anticipate though that this would suffice to prompt a more muscular fiscal policy stimulus.

**Remain Neutral on China equities.** Although this might seem questionable in the face of the impending tariff rate hike and its detrimental impact on China's economy, we expect Beijing to respond. In our base case, China is likely to raise its fiscal deficit ratio for 2025 from 3% to about 4%, likely involving greater government bond issuance and monetary easing. These two issues are likely to be the main the driver for China equities in the coming 6-12 months. While GDP growth is still likely to decelerate in 2025, and we have also lowered our MXCN targets, we still project upside from 63 currently to 67 in June 2025 and 74 in December 2025. But we do expect volatility stemming from tariff announcements, stimulus surprises—oth positive and negative—and external macroeconomic conditions to continue in the near term.

**Defensive exposure to balance downside risks and upside potential.** To benefit from potential policy stimulus in China, while still being relatively cushioned against tariff risks, investors will need to skew their China equity exposure toward defensives. We expect defensive and high-yielding value sectors to outperform. These include sectors such as financials, utilities, energy, and telecoms where the average dividend yield is around 6%, fully four percentage points above Chinese government bond (CGB) yields.

**Avoid CGBs for China convertibles and Asia IG.** In the fixed income space though, investors might need to be even more selective, and perhaps also explore a less familiar segment. While bonds do also benefit from liquidity injections, fiscal expansion is likely to be a bit of a drag on the CGB segment as supply increases. Generally, we think Asia investment grade (IG) would be the more attractive segment in the Asian bond space, especially South Korean and Indonesian IG. We think spreads there can remain tighter for longer given robust fundamentals and a positive technical picture. High absolute yield levels (a little below 5.5%) should continue to spur demand. One other interesting and potentially attractive area for China onshore investors is convertible bonds. These contain an embedded call option that provides investors with equity-like upside potential if these stimulus measures prove effective.

## Disclaimer

This document is prepared and published by the Global Wealth Management business of UBS Switzerland AG (regulated by FINMA in Switzerland), its subsidiaries or its affiliates ("UBS"), part of UBS Group AG ("UBS Group"). UBS Group includes former Credit Suisse AG, its subsidiaries, branches and affiliates. In the USA, UBS Financial Services Inc. is a subsidiary of UBS AG and a member of FINRA/SIPC. Additional Disclaimer relevant to Credit Suisse Wealth Management follows at the end of this section.

**This document and the information contained herein are provided solely for your information and UBS marketing purposes.** Nothing in this document constitutes investment research, investment advice, a sales prospectus, or an offer or solicitation to engage in any investment activities. This document is not a recommendation to buy or sell any security, investment instrument, or product, and does not recommend any specific investment program or service.

Information contained in this document has not been tailored to the specific investment objectives, personal and financial circumstances, or particular needs of any individual client. Certain investments referred to in this document may not be suitable or appropriate for all investors. In addition, certain services and products referred to in the document may be subject to legal restrictions and/or license or permission requirements and cannot therefore be offered worldwide on an unrestricted basis. No offer of any product will be made in any jurisdiction in which the offer, solicitation, or sale is not permitted, or to any person to whom it is unlawful to make such offer, solicitation, or sale.

Although all information and opinions expressed in this document were obtained in good faith from sources believed to be reliable, no representation or warranty, express or implied, is made as to the document's accuracy, sufficiency, completeness or reliability. All information and opinions expressed in this document are subject to change without notice and may differ from opinions expressed by other business areas or divisions of UBS Group. UBS is under no obligation to update or keep current the information contained herein. **The views and opinions expressed in this material by third parties are not those of UBS.** Accordingly, UBS does not accept any liability over the content shared by third parties or any claims, losses or damages arising from the use or reliance of all or any part thereof.

All pictures or images ("images") herein are for illustrative, informative or documentary purposes only and may depict objects or elements which are protected by third party copyright, trademarks and other intellectual property rights. Unless expressly stated, no relationship, association, sponsorship or endorsement is suggested or implied between UBS and these third parties.

Any charts and scenarios contained in the document are for illustrative purposes only. Some charts and/or performance figures may not be based on complete 12-month periods which may reduce their comparability and significance. Historical performance is no guarantee for, and is not an indication of future performance.

Nothing in this document constitutes legal or tax advice. UBS and its employees do not provide legal or tax advice. This document may not be redistributed or reproduced in whole or in part without the prior written permission of UBS. To the extent permitted by the law, neither UBS, nor any of its directors, officers, employees or agents accepts or assumes any liability, responsibility or duty of care for any consequences, including any loss or damage, of you or anyone else acting, or refraining to act, in reliance on the information contained in this document or for any decision based on it.

**Additional Disclaimer relevant to Credit Suisse Wealth Management:** Except as otherwise specified herein and/or depending on the local entity from which you are receiving this document, this document is distributed by UBS Switzerland AG, authorised and regulated by the Swiss Financial Market Supervisory Authority (FINMA). Your personal data will be processed in accordance with the Credit Suisse privacy statement accessible at your domicile through the official Credit Suisse website <https://www.credit-suisse.com>. In order to provide you with marketing materials concerning our products and services, UBS Group AG and its subsidiaries may process your basic personal data (i.e. contact details such as name, e-mail address) until you notify us that you no longer wish to receive them. You can optout from receiving these materials at any time by informing your Relationship Manager.

Please visit <https://www.ubs.com/global/en/wealth-management/insights/chief-investment-office/marketing-material-disclaimer.html> to read the full legal disclaimer applicable to this document.

© UBS 2024. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.